Pieris Pharmaceuticals, INC 8-K filings
Pieris Pharmaceuticals has filed an 8-K report to provide supplemental disclosures related to its merger with Palvella Therapeutics, following demands and lawsuits from stockholders alleging disclosure deficiencies.
Palvella Therapeutics has been awarded a $2.6 million grant from the FDA to support its Phase 3 trial of QTORIN rapamycin for microcystic lymphatic malformations.
Pieris Pharmaceuticals issued one share of Series F Preferred Stock to its Chairman, James Geraghty, for $1.00, granting him 25 million votes on a proposal to increase the company's authorized common stock.
Palvella Therapeutics and Pieris Pharmaceuticals have agreed to merge, creating a Nasdaq-listed biopharmaceutical company focused on rare genetic skin diseases.
8-K: Pieris Pharmaceuticals Terminates Collaboration Agreement with Servier Following Safety Concerns
Pieris Pharmaceuticals has received notice of termination from Servier for their collaboration agreement due to safety concerns in a Phase 1 clinical study, leading to the discontinuation of a key drug program.
Pieris Pharmaceuticals has regained compliance with Nasdaq listing rules after its stock price closed above $1.00 for ten consecutive days.
Pieris Pharmaceuticals has announced a 1-for-80 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
Pieris Pharmaceuticals is shifting its strategy to focus on partnered programs and potential milestone payments, aiming to extend its cash runway into 2027.